China Pharma (NYSE:CPHI) Shares Down 4.4% – Here’s Why

China Pharma Holdings, Inc. (NYSE:CPHI) shares fell 4.4% during trading on Monday . The stock traded as low as $1.07 and last traded at $1.08. 393,419 shares were traded during trading, a decline of 80% from the average daily volume of 1,922,649 shares. The stock had previously closed at $1.13.

China Pharma Price Performance

The firm has a market cap of $43.76 million, a P/E ratio of -2.51 and a beta of 1.05. The company has a current ratio of 0.79, a quick ratio of 0.26 and a debt-to-equity ratio of 0.22. The business has a 50-day moving average price of $1.10 and a 200-day moving average price of $0.82.

Hedge Funds Weigh In On China Pharma

An institutional investor recently raised its stake in China Pharma stock. Citadel Advisors LLC increased its holdings in China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,426 shares of the company’s stock after buying an additional 7,356 shares during the period. Citadel Advisors LLC owned about 0.93% of China Pharma worth $59,000 as of its most recent filing with the Securities & Exchange Commission.

China Pharma Company Profile

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.